Fineline Cube

Follow:
14420 Articles
Qyuns Therapeutics Partners with Roche for Global Rights to Long‑Acting Bispecific Antibody QX031N
CompanyDeals

Qyuns Therapeutics Partners with Roche for Global Rights to Long‑Acting Bispecific Antibody QX031N

Jiangsu Aidea Secures Approval to Launch ADC118 Tablets in China, First Domestic HIV Integrase FDC
CompanyDrug

Jiangsu Aidea Secures Approval to Launch ADC118 Tablets in China, First Domestic HIV Integrase FDC

Fosun Pharmaceutical Q3 2025 Revenue Slips 5.5% Amid VBP, Innovative Drugs Grow 18%
Company

Fosun Pharmaceutical Q3 2025 Revenue Slips 5.5% Amid VBP, Innovative Drugs Grow 18%

Junshi Biosciences Q3 2025 Revenue Climbs 31%, Toripalimab Drives Growth, NMPA Approves sNDA
Company

Junshi Biosciences Q3 2025 Revenue Climbs 31%, Toripalimab Drives Growth, NMPA Approves sNDA

Fosun Pharmaceutical Announces Spin‑Off and HK Listing of Adgenvax
CompanyDeals

Fosun Pharmaceutical Announces Spin‑Off and HK Listing of Adgenvax

Fosun Pharma Target Fund Launches with RMB 1 Billion Capital, Led by China Resources GP
CompanyDeals

Fosun Pharma Target Fund Launches with RMB 1 Billion Capital, Led by China Resources GP

Alphamab Oncology Secures FDA Fast‑Track Designation for HER2 Bispecific ADC JSKN003 in Platinum‑Resistant Ovarian Cancer
CompanyDrug

Alphamab Oncology Secures FDA Fast‑Track Designation for HER2 Bispecific ADC JSKN003 in Platinum‑Resistant Ovarian Cancer

SSY Group Limited Projected to Win 12 Products in China’s Eleventh Volume‑Based Procurement Round
Policy / Regulatory

SSY Group Limited Projected to Win 12 Products in China’s Eleventh VBP Round

Hengrui Pharmaceuticals Secures NMPA Acceptance for Fluzoparib in First‑Line Therapy of DNA‑Repair‑Defect Positive mCRPC
CompanyDrug

Hengrui Pharmaceuticals Secures NMPA Acceptance for Fluzoparib in First‑Line Therapy of DNA‑Repair‑Defect Positive mCRPC

Nanjing Leads Biolabs Announces First‑Patient Dose of LBL‑024, a Novel Bispecific Antibody for Biliary Tract Cancer
CompanyDrug

Nanjing Leads Biolabs Announces First‑Patient Dose of LBL‑024, a Novel Bispecific Antibody for Biliary Tract Cancer

Eisai and Merck Present 5‑Year Survival Data for Lenvatinib‑Pembrolizumab in Advanced Endometrial Carcinoma at ESMO 2025
CompanyDrug

Eisai and Merck Present 5‑Year Survival Data for Lenvatinib‑Pembrolizumab in Advanced Endometrial Carcinoma at ESMO 2025

PolyMed Biopharmaceuticals Completes Pre‑A++ Funding Round Led by Caleb Capital, Fuels PROTAC‑Focused Pipeline
CompanyDeals

PolyMed Biopharmaceuticals Completes Pre‑A++ Funding Round Led by Caleb Capital, Fuels PROTAC‑Focused Pipeline